Results 121 to 130 of about 54,427 (226)

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Spontaneously occurring primary canine pulmonary adenocarcinoma (cPAC) exhibits clinicopathological and molecular similarities to never‐smoker human lung cancers. Shared genomic alterations, including point mutations, indel mutations and copy number changes particularly in HER2 signalling, are significant therapeutic targets, especially for ...
Sharadha Sakthikumar, William P. D. Hendricks, David Rainford, William Selleck, Natalia Briones, Christopher Coggins, Natalie Quan, Victoria Zismann, Gwendolen Lorch, Aleksandar Sekulic, Jeffrey M. Trent   +10 more
wiley   +1 more source

ERRFI1 (ERBB receptor feedback inhibitor 1) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on ERRFI1 (ERBB receptor feedback inhibitor 1), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire   +2 more sources

Structure-function analysis of nucleolin and ErbB receptors interactions.

PLoS ONE, 2009
BackgroundThe ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail.
Keren Farin, Ayelet Di Segni, Adam Mor, Ronit Pinkas-Kramarski   +3 more
doaj   +1 more source

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Ditsch, Nina, Friese, Klaus, Kahlert, Steffen, Kümper, Carolin, Lenhard, Miriam, Rückert, Sandra, Untch, Michael   +7 more
core   +2 more sources

Identification of Crucial Drug Targets and Pathways to Reprogram Drug Resistance Through Epigenetic Modulation in Advanced Lung Cancer Using Integrated Bioinformatics Approach

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Resistance to chemotherapy, which is demonstrated in almost every patient with advanced‐stage lung cancer (ALC), underscores an urgent need to unravel the underlying molecular mechanisms and identify novel strategies to overcome drug resistance. In the present study, an attempt was made to identify epigenetic targets and modulators that can be
Okibur Rahman, Mossammat Rima Akter, Nur Alam   +2 more
wiley   +1 more source

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

Experimental Hematology & Oncology, 2018
Background Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of
John D. Strickley, Aaron C. Spalding, M. Tye Haeberle, Timothy Brown, Don A. Stevens, Jae Jung   +5 more
doaj   +1 more source

An uncommon subtype of breast carcinoma in a man: The pure mucinous carcinoma [PDF]

, 2011
Aim: Our purpose is to describe a new case of pure mucinous carcinoma in a man, to put emphasis on the rarity of this histologic subtype and the problems of management due to the fewer reported cases in the literature and to compare it with the female ...
Sawssen Dhambri , Mona Mlika , Aïda Ayadi-Kaddour , Abdelfattah Zeddini , Faouzi El Mezni , Int J Cur Biomed Phar Res.
core  

Sensing and Reprogramming Surface Receptor Activation With Synthetic Transcriptional Circuits

Advanced Science, Volume 13, Issue 25, 4 May 2026.
A synthetic receptor‐signalling induced transcription (RESIT) circuit is designed based on receptor activation mediated split protease complementation and release of membrane‐tethered synthetic transcriptional modules. The RESIT system enables probing Ca2+ entry, receptor tyrosine kinase (RTK) activities and Ras activation, and reprogramming RTK ...
Fei Liu, Mei Yuan, Li‐Juan Tang, Fenglin Wang, Xia Chu, Jian‐Hui Jiang   +5 more
wiley   +1 more source

RANKL Signaling and ErbB Receptors in Breast Carcinogenesis

Trends in Molecular Medicine, 2016
ErbB family members, ErbB1/EGFR/HER-1, ErbB2/HER-2, ErbB3/HER-3 and ErbB4/HER-4, have been implicated in breast cancer (BC) tumorigenicity. Recently, crucial roles for RANK/RANKL signaling in addition to key downstream factor NF-κB have been demonstrated in mammary tumorigenesis.
Zoi, I., Karamouzis, M.V., Adamopoulos, C., Papavassiliou, A.G.   +3 more
openaire   +3 more sources

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

, 2005
Introduction: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Gunter von Minckwitz, Sebastian Harder, Sascha Hövelmann, Elke Jäger, Salah-Eddin Al-Batran, Sibylle Loibl, Akin Atmaca, Christian Cimpoiasu, Antje Neumann, Aklil Abera, Alexander Knuth, Manfred Kaufmann, Dirk Jäger, Alexander B Maurer, Winfried S Wels, MA Olayioye, Y Yarden, J Mendelsohn, DJ Slamon, CL Vogel, I Pastan, W Wels, RJ Kreitman, W Wels, W Wels, IM Harwerth, BH Iglewski, A Keppler-Hafkemeyer, M Schmidt, A Spyridonidis, M Azemar, L Wang, U Altenschmidt, M Maurer-Gebhard, JK Batra, Y Reiter, LH Pai-Scherf, M Azemar, WMA, M Maurer-Gebhard, FDA, J Schumann, M Onda, NJ Olsen, YL Yip, B Gerstmayer, DL Keefe, HS Cho, RJ Kreitman, RJ Kreitman   +49 more
core   +1 more source